Marijuana Rescheduling — A Game Changer for Research?
Por: Haffajee, Rebecca L [Autor]
Colaborador(es): Mikos, Robert A | Cooper, Ziva DTipo de material: 
TextoIdioma: Inglés Descripción: páginas: 729-731Tema(s): MEDICAMENTOS, DISPOSITIVOS Y LA FDA | HEMATOLOGÍA | ONCOLOGÍA GENERAL | DOLOR | TRATAMIENTOS EN ONCOLOGÍA | DERECHO SANITARIO
En: The New England Journal of MedicineResumen: On April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled.
| Tipo de ítem | Ubicación actual | Colección | Signatura | Info Vol | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
Títulos de Revistas
|
Biblioteca Central ESSALUD | Colección General | NEJM (Navegar estantería) | Vol.395, No.8 (2026) | Disponible | NEJM12 |
On April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled.